Expected revenue growth
As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.
The above graph compares Biogen’s revenues since the first quarter of 2017 with the third-quarter estimates. Multiple sclerosis products contributed nearly 65% of the total revenues, while spinal muscular atrophy products contributed over 12% of Biogen’s total revenues.
Biogen’s multiple sclerosis products include Tecfidera, Interferon, Tysabri, and other products. Tecfidera is Biogen’s largest revenue contributor at ~32% of the total revenues. During the third quarter, Tecfidera’s revenues are expected to grow in the international markets, partially offset by lower sales in the US markets.
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter due to lower sales across the US markets and international markets.
Spinraza, a spinal muscular atrophy product, contributed ~12% of Biogen’s total revenues. Spinraza is expected to report growth during the third quarter following strong uptake in international markets and increased sales from the US markets.
Analysts also expect the revenues from biosimilars and Anti-CD20 therapeutic programs to increase during the third quarter.